NCT01774058 (ILOFLOW) is a Phase 2 clinical trial of Ilomedin in Diabetes, sponsored by Prim PD Dr Afshin Assadian.

Who is sponsoring NCT01774058?

NCT01774058 is sponsored by Prim PD Dr Afshin Assadian.

What drugs are being tested in NCT01774058?

Interventions in NCT01774058: Ilomedin.

What condition does NCT01774058 study?

NCT01774058 studies Diabetes, Arteriosclerosis, Peripheral Arterial Occlusive Disease, Neuropathy.

Is NCT01774058 still recruiting?

NCT01774058 is currently status unknown. Last updated 16 October 2018.

Last reviewed 2018-10-16 · How we verify

NCT01774058: ILOFLOW

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Intraoperative Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation in Diabetics and Non-diabetics: Implication for Outcome-prediction and Perioperative Therapy

Status unknown Phase 2 Last updated 16 October 2018

What this trial tests

Phase 2 trial testing Ilomedin in Diabetes in 100 participants. Status unknown.

Timeline

1 October 2012

Primary endpoint
1 June 2019

1 June 2019

Quick facts

Lead sponsor	Prim PD Dr Afshin Assadian
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 October 2012
Primary completion	1 June 2019
Estimated completion	1 June 2019
Sites	1 location across Austria

Drugs / interventions tested

Ilomedin — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Arteriosclerosis — all drugs for Arteriosclerosis →
Peripheral Arterial Occlusive Disease — all drugs for Peripheral Arterial Occlusive Disease →
Neuropathy — all drugs for Neuropathy →

Sponsor

Prim PD Dr Afshin Assadian — full company profile →

Who can join

18 and older, any sex, with Diabetes or Arteriosclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.
Time frame: 6 weeks after surgery
Before surgery reconstruction the first measurement with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument will be done on the common femoral artery and then after surgery reconstruction. Therefore there will be different measuring heads exactly fitting around the vessels. Then the administration of 3000ng Ilomedin® in 15ml saline will be injected into the common femoral artery via a

Sponsor's own description

A prospective case-control study was performed to investigate the effect of iloprost on the intraoperative flow volume in diabetic and non-diabetic patients as well as the effect of peripheral neuropathy in patients with peripheral arterial occlusive disease (PAOD) undergoing arterial reconstruction (primary endpoint). 100 patients undergoing femoral artery reconstruction or femorodistal bypass surgery were included. Prior to surgery, peripheral nerve conduction velocity was measured. Blood flow volume at the common femoral artery was assessed using a Doppler flowmeter (Sono TT FlowLab; ) before reconstruction, prior to the intraarterial application of 3000ng of iloprost and 5 and 10 minutes afterwards. Peripheral resistance units (PRU) were calculated as a function of mean systemic arterial pressure (MAP) and flow volume (VF): PRU = MAP (mmHg) / VF (ml/min).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01774058 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prim PD Dr Afshin Assadian
Last refreshed: 16 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01774058.